603392 万泰生物
交易中 09-11 09:55:23
资讯
新帖
简况
万泰生物最新公告：实控人钟睒睒捐赠股份完成过户持股比例降至15.10%
证券之星 · 09-04
万泰生物最新公告：实控人钟睒睒捐赠股份完成过户持股比例降至15.10%
每周股票复盘：万泰生物（603392）实控人拟捐3300万股公司股份
证券之星 · 08-30
每周股票复盘：万泰生物（603392）实控人拟捐3300万股公司股份
8月26日万泰生物涨10.00%，疫苗ETF国泰基金重仓该股
证券之星 · 08-26
8月26日万泰生物涨10.00%，疫苗ETF国泰基金重仓该股
万泰生物：公司九价HPV疫苗生产正常运行，可持续、稳定且充足地供应市场
证券之星 · 08-26
万泰生物：公司九价HPV疫苗生产正常运行，可持续、稳定且充足地供应市场
万泰生物（603392）披露实际控制人无偿捐赠部分公司股份公告，8月25日股价上涨0.04%
证券之星 · 08-25
万泰生物（603392）披露实际控制人无偿捐赠部分公司股份公告，8月25日股价上涨0.04%
万泰生物：实控人钟睒睒捐赠3300万股公司股份
格隆汇 · 08-25
万泰生物：实控人钟睒睒捐赠3300万股公司股份
8月24日万泰生物跌8.17%，疫苗ETF国泰基金重仓该股
证券之星 · 08-24
8月24日万泰生物跌8.17%，疫苗ETF国泰基金重仓该股
每周股票复盘：万泰生物（603392）Q2营收增18.55%，股东户数增2.61%
证券之星 · 08-23
每周股票复盘：万泰生物（603392）Q2营收增18.55%，股东户数增2.61%
8月20日万泰生物涨10.00%，疫苗ETF国泰基金重仓该股
证券之星 · 08-20
8月20日万泰生物涨10.00%，疫苗ETF国泰基金重仓该股
万泰生物（603392）披露2026年半年度募集资金存放、管理与实际使用情况专项报告，8月19日股价下跌2.74%
证券之星 · 08-19
万泰生物（603392）披露2026年半年度募集资金存放、管理与实际使用情况专项报告，8月19日股价下跌2.74%
图解万泰生物中报：第二季度单季净利润同比增长6.50%
证券之星 · 08-19
图解万泰生物中报：第二季度单季净利润同比增长6.50%
万泰生物(603392.SH)发布半年度业绩，归母净亏损1.28亿元
智通财经 · 08-19
万泰生物(603392.SH)发布半年度业绩，归母净亏损1.28亿元
万泰生物(603392)6月30日股东户数4.29万户，较上期增加2.61%
证券之星 · 08-19
万泰生物(603392)6月30日股东户数4.29万户，较上期增加2.61%
每周股票复盘：万泰生物（603392）九价HPV疫苗获泰国上市许可
证券之星 · 08-16
每周股票复盘：万泰生物（603392）九价HPV疫苗获泰国上市许可
股市必读：万泰生物新发布《万泰生物关于使用部分闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告》
证券之星 · 08-14
股市必读：万泰生物新发布《万泰生物关于使用部分闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告》
万泰生物：若相关疫苗在有效期内正常实现销售，公司将按规定转回相应的存货跌价准备
证券之星 · 08-13
万泰生物：若相关疫苗在有效期内正常实现销售，公司将按规定转回相应的存货跌价准备
万泰生物：收取技术许可和各类销售及服务费用
证券之星 · 08-13
万泰生物：收取技术许可和各类销售及服务费用
万泰生物：公司高度重视九价HPV疫苗在9-17岁人群 "2针法"的差异化接种优势
证券之星 · 08-13
万泰生物：公司高度重视九价HPV疫苗在9-17岁人群 "2针法"的差异化接种优势
万泰生物：公司将立足主业发展，不断提升经营质量与内在价值
证券之星 · 08-13
万泰生物：公司将立足主业发展，不断提升经营质量与内在价值
万泰生物：创新疫苗商业化受多重因素影响
证券之星 · 08-13
万泰生物：创新疫苗商业化受多重因素影响
加载更多
公司概况
公司名称：
北京万泰生物药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-04-29
主营业务：
北京万泰生物药业股份有限公司的主营业务是诊断试剂、疫苗以及医疗器械的研发、生产和销售。公司的主要产品是体外诊断试剂、诊断仪器、重组戊型肝炎疫苗、二价HPV疫苗、鼻喷流感病毒载体新冠肺炎疫苗、九价HPV疫苗。
发行价格：
8.75
{"stockData":{"symbol":"603392","market":"SH","secType":"STK","nameCN":"万泰生物","latestPrice":26.4,"timestamp":1789091723000,"preClose":27.24,"halted":0,"volume":1988729,"delay":0,"changeRate":-0.0308,"floatShares":1264000000,"shares":1264000000,"eps":-0.3026,"marketStatus":"交易中","change":-0.84,"latestTime":"09-11 09:55:23","open":27.02,"high":27.02,"low":26.32,"amount":52893000,"amplitude":0.0257,"askPrice":26.4,"askSize":8,"bidPrice":26.39,"bidSize":12,"shortable":0,"etf":0,"ttmEps":-0.3026,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1789097400000},"marketStatusCode":2,"adr":0,"adjPreClose":27.24,"symbolType":"stock","openAndCloseTimeList":[[1789090200000,1789097400000],[1789102800000,1789110000000]],"highLimit":29.96,"lowLimit":24.52,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1264392804,"isCdr":false,"pbRate":2.93,"roa":"--","roe":"--","epsLYR":-0.31,"committee":0.338318,"marketValue":33380000000,"turnoverRate":0.0016,"status":1,"floatMarketCap":33380000000},"requestUrl":"/m/hq/s/603392/","defaultTab":"news","newsList":[{"id":"2664352063","title":"万泰生物最新公告：实控人钟睒睒捐赠股份完成过户持股比例降至15.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664352063","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664352063?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:10","pubTimestamp":1788516610,"startTime":"0","endTime":"0","summary":"万泰生物(603392.SH)公告称，公司实际控制人钟睒睒向福建省翔安创新实验室科技发展基金会无偿捐赠其直接持有的3300万股无限售条件流通股，占公司总股本的2.61%，已完成过户登记手续。本次权益变动后，钟睒睒直接持股比例由17.71%降至15.10%，其与一致行动人养生堂有限公司合计持股比例由73.53%降至70.92%。本次权益变动不触及要约收购，不会导致公司控股股东及实际控制人发生变化。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400032695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09633","603392","BK1589","LU1981816686.USD","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663101380","title":"每周股票复盘：万泰生物（603392）实控人拟捐3300万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2663101380","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663101380?lang=zh_cn&edition=full","pubTime":"2026-08-30 03:08","pubTimestamp":1788030493,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，万泰生物报收于30.37元，较上周的30.59元下跌0.72%。本周，万泰生物8月27日盘中最高价报32.44元。万泰生物当前最新总市值384.0亿元，在医疗器械板块市值排名4/129，在两市A股市值排名528/5211。本次捐赠后，钟睒睒先生及其一致行动人合计持股比例由73.53%降至70.92%，不会导致公司控制权变化，不影响公司治理结构及持续经营。受赠方承诺受让股份后6个月内不减持，未来减持将与钟睒睒先生合并计算减持额度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","603392","BK1200","BK0239","LU1981816686.USD","09633"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662679647","title":"8月26日万泰生物涨10.00%，疫苗ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662679647","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662679647?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:32","pubTimestamp":1787733154,"startTime":"0","endTime":"0","summary":"证券之星消息，8月26日万泰生物涨10.00%，收盘报30.91元，换手率0.64%，成交量8.11万手，成交额2.45亿元。融资融券方面近5日融资净流出256.48万，融资余额减少；融券净流出100.0，融券余额减少。重仓万泰生物的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为国泰基金的疫苗ETF国泰。疫苗ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600036586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159643","09633","603392","BK1589","LU1981816686.USD","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662793748","title":"万泰生物：公司九价HPV疫苗生产正常运行，可持续、稳定且充足地供应市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2662793748","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662793748?lang=zh_cn&edition=full","pubTime":"2026-08-26 15:33","pubTimestamp":1787729615,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好、请问目前国内的万泰HPV9价疫苗是否有供不应求的情况？万泰生物回复：您好！公司九价HPV疫苗生产正常运行，可持续、稳定且充足地供应市场。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600030000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","09633","159646","BK1200","LU1981816686.USD","BK1589","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775874","title":"万泰生物（603392）披露实际控制人无偿捐赠部分公司股份公告，8月25日股价上涨0.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775874","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662775874?lang=zh_cn&edition=full","pubTime":"2026-08-25 22:25","pubTimestamp":1787667953,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，万泰生物报收于28.1元，较前一交易日上涨0.04%，最新总市值为355.29亿元。近日，万泰生物发布《关于实际控制人无偿捐赠部分公司股份的公告》。公告显示，公司实际控制人钟睒睒先生拟向福建省翔安创新实验室科技发展基金会无偿捐赠其直接持有的公司33,000,000股无限售条件流通股，占公司总股本的2.61%。受赠方承诺受让股份后6个月内不减持，未来减持将与钟睒睒先生合并计算减持额度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500050851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","09633","BK1200","LU1981816686.USD","BK1589","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778082","title":"万泰生物：实控人钟睒睒捐赠3300万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778082","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662778082?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:12","pubTimestamp":1787649121,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661212682","title":"8月24日万泰生物跌8.17%，疫苗ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661212682","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661212682?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:31","pubTimestamp":1787560281,"startTime":"0","endTime":"0","summary":"证券之星消息，8月24日万泰生物跌8.17%，收盘报28.09元，换手率1.11%，成交量14.07万手，成交额4.11亿元。重仓万泰生物的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为国泰基金的疫苗ETF国泰。疫苗ETF国泰目前规模为1.4亿元，最新净值0.5822，较上一交易日下跌3.63%，近一年下跌11.36%。疫苗ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400021785.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","09633","BK1200","LU1981816686.USD","BK1589","BK0239","159643"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661211928","title":"每周股票复盘：万泰生物（603392）Q2营收增18.55%，股东户数增2.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661211928","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661211928?lang=zh_cn&edition=full","pubTime":"2026-08-23 01:50","pubTimestamp":1787421022,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，万泰生物报收于30.59元，较上周的30.1元上涨1.63%。本周，万泰生物8月21日盘中最高价报32.55元。股本股东变化股东户数变动截至2026年6月30日，万泰生物股东户数为4.29万户，较3月31日增加1091.0户，增幅2.61%。公司公告汇总万泰生物2026年半年度报告摘要公司总资产为13,706,430,854.69元，较上年度末减少2.40%；归属于上市公司股东的净资产为11,736,292,175.72元，较上年度末减少1.08%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660402106","title":"8月20日万泰生物涨10.00%，疫苗ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660402106","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660402106?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:34","pubTimestamp":1787214894,"startTime":"0","endTime":"0","summary":"证券之星消息，8月20日万泰生物涨10.00%，收盘报30.81元，换手率0.54%，成交量6.83万手，成交额2.09亿元。重仓万泰生物的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为国泰基金的疫苗ETF国泰。疫苗ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000028808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","09633","LU1981816686.USD","603392","BK0239","159643","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660297624","title":"万泰生物（603392）披露2026年半年度募集资金存放、管理与实际使用情况专项报告，8月19日股价下跌2.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660297624","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660297624?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:30","pubTimestamp":1787149829,"startTime":"0","endTime":"0","summary":"截至2026年8月19日收盘，万泰生物报收于28.01元，较前一交易日下跌2.74%，最新总市值为354.16亿元。近日，北京万泰生物药业股份有限公司披露2026年半年度募集资金存放、管理与实际使用情况。2026年上半年，公司实际投入募集资金项目7,695.77万元，截至2026年6月30日，募集资金余额为131,535.81万元，其中专户余额26,785.81万元，保本型理财产品余额104,750.00万元。公司对募集资金实行专户存储，签署三方及四方监管协议，规范使用募集资金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900043391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","BK0239","603392","BK1200","09633","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660133444","title":"图解万泰生物中报：第二季度单季净利润同比增长6.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660133444","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660133444?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:16","pubTimestamp":1787134581,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物2026年中报显示，上半年度公司主营收入10.48亿元，同比上升24.29%；归母净利润-1.28亿元，同比上升10.92%；扣非净利润-1.69亿元，同比上升30.39%；其中2026年第二季度，公司单季度主营收入5.25亿元，同比上升18.55%；单季度归母净利润-8533.23万元，同比上升6.5%；单季度扣非净利润-1.04亿元，同比上升24.2%；负债率13.17%，投资收益3260.24万元，财务费用910.04万元，毛利率63.91%。财报数据概要请见下图:本文数据来源于万泰生物2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900031993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","09633"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660441764","title":"万泰生物(603392.SH)发布半年度业绩，归母净亏损1.28亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660441764","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660441764?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:02","pubTimestamp":1787133779,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万泰生物(603392.SH)披露2026年半年度报告，报告期公司实现营业收入10.48亿元，同比增长24.29%;归属于上市公司股东的净利润亏损1.28亿元，同比收窄;扣非净利润亏损1.69亿元，同比收窄;基本每股收益-0.10元。营业收入增长，主要是九价HPV疫苗上市后持续推进终端准入销售放量，疫苗板块营业收入较上年同期增加。归属于上市公司股东的净利润较上年同期亏损有所收窄，原因同上述营业收入影响因素。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603392","BK1200","BK1589","BK0239","09633","LU1981816686.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660441791","title":"万泰生物(603392)6月30日股东户数4.29万户，较上期增加2.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660441791","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660441791?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:02","pubTimestamp":1787133723,"startTime":"0","endTime":"0","summary":"证券之星消息，近日万泰生物披露，截至2026年6月30日公司股东户数为4.29万户，较3月31日增加1091.0户，增幅为2.61%。在医疗器械行业个股中，万泰生物股东户数高于行业平均水平，截至6月30日，医疗器械行业平均股东户数为2.15万户。从股价来看，2026年3月31日至2026年6月30日，万泰生物区间跌幅为32.15%，在此期间股东户数增加1091.0户，增幅为2.61%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900031479.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","09633","BK0239","603392","BK1589","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659175048","title":"每周股票复盘：万泰生物（603392）九价HPV疫苗获泰国上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2659175048","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659175048?lang=zh_cn&edition=full","pubTime":"2026-08-16 02:28","pubTimestamp":1786818492,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，万泰生物报收于30.1元，较上周的30.53元下跌1.41%。本周，万泰生物8月12日盘中最高价报31.89元。本周关注点来自公司公告汇总：九价HPV疫苗获泰国上市许可，系首个境外上市许可。公司公告汇总万泰生物关于公司九价HPV疫苗获得泰国上市许可的公告北京万泰生物药业股份有限公司全资子公司厦门万泰沧海生物技术有限公司自主研发的九价HPV疫苗获得泰国食品药品监督管理局批准，成为该产品首个境外上市许可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","09633","BK1589","LU1981816686.USD","603392","BK0239","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659619791","title":"股市必读：万泰生物新发布《万泰生物关于使用部分闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659619791","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659619791?lang=zh_cn&edition=full","pubTime":"2026-08-14 02:08","pubTimestamp":1786644495,"startTime":"0","endTime":"0","summary":"公司公告汇总万泰生物关于使用部分闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告北京万泰生物药业股份有限公司使用部分闲置募集资金35,000.00万元进行现金管理，购买民生银行和浦发银行的结构性存款产品，期限分别为364天和360天，产品均为保本浮动收益型，不影响募投项目实施。公司管理层始终高度重视全体股东利益，持续密切关注公司股价及资本市场情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400001332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","603392","BK1200","LU1981816686.USD","BK0239","09633"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659310861","title":"万泰生物：若相关疫苗在有效期内正常实现销售，公司将按规定转回相应的存货跌价准备","url":"https://stock-news.laohu8.com/highlight/detail?id=2659310861","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659310861?lang=zh_cn&edition=full","pubTime":"2026-08-13 15:33","pubTimestamp":1786606398,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物08月13日在投资者关系平台上答复投资者关心的问题。具体计提金额及相关情况请详见公司相关信息披露。关于已计提减值存货的后续处理：若相关疫苗在有效期内正常实现销售，公司将按规定转回相应的存货跌价准备，对当期营业收入和利润均产生正向影响。公司始终严格遵守疫苗管理相关法律法规，确保每一支上市疫苗的质量安全。感谢您对公司的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300020186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","BK1589","BK0239","09633","BK1200","159646","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659131725","title":"万泰生物：收取技术许可和各类销售及服务费用","url":"https://stock-news.laohu8.com/highlight/detail?id=2659131725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659131725?lang=zh_cn&edition=full","pubTime":"2026-08-13 15:33","pubTimestamp":1786606395,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物08月13日在投资者关系平台上答复投资者关心的问题。贵司出口原液和标准。那么本地化生产成品疫苗后销售环节，是否也有利益分成？公司与泰国和印尼本土伙伴一起，按照已签署的合作协议，合力推进九价HPV疫苗本土化生产相关落地工作。公司依据双方的合作方式及合同约定，收取技术许可和各类销售及服务费用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300020183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1981816686.USD","09633","BK1589","BK1200","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659131225","title":"万泰生物：公司高度重视九价HPV疫苗在9-17岁人群 \"2针法\"的差异化接种优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2659131225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659131225?lang=zh_cn&edition=full","pubTime":"2026-08-13 15:33","pubTimestamp":1786606395,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物08月13日在投资者关系平台上答复投资者关心的问题。投资者提问：国产九价HPV疫苗与进口的疫苗在14岁和17岁之间有少打一针的差异化优势，建议公司集中力量在这个年龄段搞好宣传工作，提高疫苗的普及率。公司高度重视九价HPV疫苗在9-17岁人群 \"2针法\"的差异化接种优势，正积极通过学术推广、科普教育等多种方式提升该年龄段的接种认知和普及率。公司第三代HPV疫苗临床前研究按计划有序进行中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300020181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK1589","BK0239","09633","BK1200","LU1981816686.USD","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659317981","title":"万泰生物：公司将立足主业发展，不断提升经营质量与内在价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2659317981","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659317981?lang=zh_cn&edition=full","pubTime":"2026-08-13 15:33","pubTimestamp":1786606394,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)08月13日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好！巨亏的智飞生物拟斥资1.5-3亿元回购股票，体现了一种责任担当。公司管理层有何感想？万泰生物回复：您好！公司管理层始终高度重视全体股东利益，持续密切关注公司股价及资本市场情况。股份回购涉及公司资金使用、长期研发与产业布局等多重因素，需要充分论证、统筹权衡。公司将立足主业发展，不断提升经营质量与内在价值；若后续筹划相关资本运作事项，将严格按照监管规则及时履行信息披露义务。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300020180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","BK1200","BK1589","LU1981816686.USD","09633","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659131226","title":"万泰生物：创新疫苗商业化受多重因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2659131226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659131226?lang=zh_cn&edition=full","pubTime":"2026-08-13 15:33","pubTimestamp":1786606394,"startTime":"0","endTime":"0","summary":"创新疫苗商业化受公众认知、行业竞争、政策环境等多重因素影响，存在较大不确定性。公司戊肝疫苗属于全球首创品种，疾病认知培育周期漫长；二价 HPV 疫苗上市后市场竞争、需求格局发生超预期变化；鼻喷新冠疫苗需求受外部防疫形势影响较大。当前九价 HPV 疫苗市场竞争充分，团队充分吸取过往经验，把控产能释放节奏，加快各省准入与渠道推广，密切跟踪终端需求，多措并举推动产品放量。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300020176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1589","BK1200","09633","LU1981816686.USD","159646","603392"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789091729712,"stockEarnings":[{"period":"1week","weight":-0.0364},{"period":"1month","weight":-0.113},{"period":"3month","weight":-0.0772},{"period":"6month","weight":-0.3147},{"period":"1year","weight":-0.5392},{"period":"ytd","weight":-0.3939}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0001},{"period":"3month","weight":-0.0241},{"period":"6month","weight":-0.0393},{"period":"1year","weight":0.032},{"period":"ytd","weight":-0.0087}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京万泰生物药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"42923人(较上一季度增加2.61%)","perCapita":"29457股","listingDate":"2020-04-29","address":"北京市昌平区科学园路31号","registeredCapital":"126439万元","survey":" 北京万泰生物药业股份有限公司的主营业务是诊断试剂、疫苗以及医疗器械的研发、生产和销售。公司的主要产品是体外诊断试剂、诊断仪器、重组戊型肝炎疫苗、二价HPV疫苗、鼻喷流感病毒载体新冠肺炎疫苗、九价HPV疫苗。","listedPrice":8.75},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万泰生物(603392)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万泰生物(603392)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万泰生物,603392,万泰生物股票,万泰生物股票老虎,万泰生物股票老虎国际,万泰生物行情,万泰生物股票行情,万泰生物股价,万泰生物股市,万泰生物股票价格,万泰生物股票交易,万泰生物股票购买,万泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万泰生物(603392)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万泰生物(603392)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}